ArticleLipids in health and disease2025
Gene expression profiling of KLF4 and KLF5 in visceral adipose tissue of obese women: insights into adipogenic and metabolic regulation.
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs global obesity rates rise, women are disproportionately affected, placing them at elevated risk for both metabolic dysfunction and cardiovascular complications. This study investigated the expression of Krüppel-like transcription factors KLF4 and KLF5 in visceral adipose tissue (VAT) from obese women to explore their potential roles in the pathogenesis of metabolic dysfunction.
methodsIn this case–control study, 46 women undergoing laparoscopic surgery were categorized into obese (n = 24) and non-obese control (n = 22) groups. VAT samples were analyzed for KLF4 and KLF5 mRNA expression using quantitative RT-PCR, normalized to GAPDH. Serum biomarkers related to glycemic status, lipid metabolism, adiposity indices, and cardiovascular risk were measured with automated clinical analyzers. Gene expression was correlated with metabolic parameters using Pearson and Spearman tests, with false discovery rate (FDR) correction for multiple comparisons.
resultsKLF4 and KLF5 expression levels did not differ significantly between groups. However, in the obese group, KLF4 expression showed positive correlations with HOMA-IR, HbA1c, fasting insulin, and glucose—indicating links to insulin resistance and glycemic regulation. In contrast, KLF5 expression was associated with lipid-related and cardiovascular parameters, including LDL-C, total cholesterol, CK-MB, and waist-to-hip ratio. In non-obese women, KLF4 and KLF5 exhibited coordinated expression, though their associations with metabolic traits were less pronounced. These findings indicate a BMI-dependent modulation of the KLF4/KLF5 regulatory axis, with obesity amplifying its links to dysglycemia and dyslipidemia.
conclusionThe KLF4/KLF5 transcriptional axis exhibits obesity-related regulatory shifts that may contribute to cardiometabolic dysfunction. These patterns highlight the potential utility of KLF4 and KLF5 as biomarkers for risk stratification, informing the development of tissue-specific therapeutic strategies aimed at improving metabolic outcomes in obese women, while ensuring that translational approaches remain safe, equitable, and targeted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.